A citation-based method for searching scientific literature


List of co-cited articles
11 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
853
100

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
328
66

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
696
66


Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Tatiana Popova, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy,[...]. Cancer Res 2012
299
66


State-of-the-art strategies for targeting the DNA damage response in cancer.
Patrick G Pilié, Chad Tang, Gordon B Mills, Timothy A Yap. Nat Rev Clin Oncol 2019
315
66

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Timothy A Yap, Brent O'Carrigan, Marina S Penney, Joline S Lim, Jessica S Brown, Maria J de Miguel Luken, Nina Tunariu, Raquel Perez-Lopez, Daniel Nava Rodrigues, Ruth Riisnaes,[...]. J Clin Oncol 2020
41
66

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Johnathan A Watkins, Sheeba Irshad, Anita Grigoriadis, Andrew N J Tutt. Breast Cancer Res 2014
152
66

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
66

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, Sandrine Boyault, Anieta M Sieuwerts,[...]. Nat Med 2017
354
66

Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma.
Jie Tang, Yanxiang Tang, Jun Yang, Si Huang. Gynecol Oncol 2012
53
33

Interpretation of somatic POLE mutations in endometrial carcinoma.
Alicia León-Castillo, Heidi Britton, Melissa K McConechy, Jessica N McAlpine, Remi Nout, Stefan Kommoss, Sara Y Brucker, Joseph W Carlson, Elisabeth Epstein, Tilman T Rau,[...]. J Pathol 2020
51
33

Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles.
Ryusuke Murakami, Noriomi Matsumura, J B Brown, Zhipeng Wang, Ken Yamaguchi, Kaoru Abiko, Yumiko Yoshioka, Junzo Hamanishi, Tsukasa Baba, Masafumi Koshiyama,[...]. Gynecol Oncol 2016
16
33

Integrated analysis of germline and somatic variants in ovarian cancer.
Krishna L Kanchi, Kimberly J Johnson, Charles Lu, Michael D McLellan, Mark D M Leiserson, Michael C Wendl, Qunyuan Zhang, Daniel C Koboldt, Mingchao Xie, Cyriac Kandoth,[...]. Nat Commun 2014
179
33

Prognostic significance of POLE proofreading mutations in endometrial cancer.
David N Church, Ellen Stelloo, Remi A Nout, Nadejda Valtcheva, Jeroen Depreeuw, Natalja ter Haar, Aurelia Noske, Frederic Amant, Ian P M Tomlinson, Peter J Wild,[...]. J Natl Cancer Inst 2014
161
33

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
Brooke E Howitt, Sachet A Shukla, Lynette M Sholl, Lauren L Ritterhouse, Jaclyn C Watkins, Scott Rodig, Elizabeth Stover, Kyle C Strickland, Alan D D'Andrea, Catherine J Wu,[...]. JAMA Oncol 2015
330
33

A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer.
Partha Basu, Ajay Mehta, Minish Jain, Sudeep Gupta, Rajnish V Nagarkar, Subhashini John, Robert Petit. Int J Gynecol Cancer 2018
55
33

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.
Yong Qin, Suhendan Ekmekcioglu, Marie-Andrée Forget, Lorant Szekvolgyi, Patrick Hwu, Elizabeth A Grimm, Amir A Jazaeri, Jason Roszik. Front Immunol 2017
38
33

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.
Stefan Kommoss, Boris Winterhoff, Ann L Oberg, Gottfried E Konecny, Chen Wang, Shaun M Riska, Jian-Bing Fan, Matthew J Maurer, Craig April, Viji Shridhar,[...]. Clin Cancer Res 2017
49
33

HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes.
Lisa Vermij, Nanda Horeweg, Alicia Leon-Castillo, Tessa A Rutten, Linda R Mileshkin, Helen J Mackay, Alexandra Leary, Melanie E Powell, Naveena Singh, Emma J Crosbie,[...]. Cancers (Basel) 2020
8
33

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.
W A Peters, P Y Liu, R J Barrett, R J Stock, B J Monk, J S Berek, L Souhami, P Grigsby, W Gordon, D S Alberts. J Clin Oncol 2000
33

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
519
33

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Krishnansu S Tewari, Robert A Burger, Danielle Enserro, Barbara M Norquist, Elizabeth M Swisher, Mark F Brady, Michael A Bookman, Gini F Fleming, Helen Huang, Howard D Homesley,[...]. J Clin Oncol 2019
126
33

Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Amanda N Fader, Dana M Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko Chambers, Angeles Alvarez Secord, Laura Havrilesky, David M O'Malley,[...]. Clin Cancer Res 2020
33
33

Biomarkers for Homologous Recombination Deficiency in Cancer.
Michal M Hoppe, Raghav Sundar, David S P Tan, Anand D Jeyasekharan. J Natl Cancer Inst 2018
94
33

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote,[...]. Ann Oncol 2019
225
33

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
Alicia León-Castillo, Stephanie M de Boer, Melanie E Powell, Linda R Mileshkin, Helen J Mackay, Alexandra Leary, Hans W Nijman, Naveena Singh, Pamela M Pollock, Paul Bessette,[...]. J Clin Oncol 2020
80
33

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.
Alison Backen, Andrew G Renehan, Andrew R Clamp, Carlo Berzuini, Cong Zhou, Amit Oza, Selina Bannoo, Stefan J Scherer, Rosamonde E Banks, Caroline Dive,[...]. Clin Cancer Res 2014
47
33


Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
Stephanie M de Boer, Melanie E Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Petronella B Ottevanger, Jonathan A Ledermann, Pearly Khaw, Romerai D'Amico,[...]. Lancet Oncol 2019
137
33

Human papillomavirus: E6 and E7 oncogenes.
Gaëlle Boulet, Caroline Horvath, Davy Vanden Broeck, Shaira Sahebali, Johannes Bogers. Int J Biochem Cell Biol 2007
72
33

Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.
Alfonso Dueñas-González, Juan J Zarbá, Firuza Patel, Juan C Alcedo, Semir Beslija, Luis Casanova, Pittayapoom Pattaranutaporn, Shahid Hameed, Julie M Blair, Helen Barraclough,[...]. J Clin Oncol 2011
264
33

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti,[...]. Int J Gynecol Cancer 2021
118
33


Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Suzy Scholl, Marina Popovic, Anne de la Rochefordiere, Elodie Girard, Sylvain Dureau, Aljosa Mandic, Katarina Koprivsek, Nina Samet, Marius Craina, Madalin Margan,[...]. EBioMedicine 2019
16
33


CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
Katherine C Kurnit, Grace N Kim, Bryan M Fellman, Diana L Urbauer, Gordon B Mills, Wei Zhang, Russell R Broaddus. Mod Pathol 2017
100
33

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
Gottfried E Konecny, Chen Wang, Habib Hamidi, Boris Winterhoff, Kimberly R Kalli, Judy Dering, Charles Ginther, Hsiao-Wang Chen, Sean Dowdy, William Cliby,[...]. J Natl Cancer Inst 2014
201
33

DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
David N Church, Sarah E W Briggs, Claire Palles, Enric Domingo, Stephen J Kearsey, Jonathon M Grimes, Maggie Gorman, Lynn Martin, Kimberley M Howarth, Shirley V Hodgson,[...]. Hum Mol Genet 2013
200
33

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
33

Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability.
Madhura Deshpande, Phillip A Romanski, Zev Rosenwaks, Jeannine Gerhardt. Cancers (Basel) 2020
13
33

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
B G Wortman, T Bosse, R A Nout, L C H W Lutgens, E M van der Steen-Banasik, H Westerveld, H van den Berg, A Slot, K A J De Winter, K W Verhoeven-Adema,[...]. Gynecol Oncol 2018
76
33

Incorporation of molecular characteristics into endometrial cancer management.
Lisa Vermij, Vincent Smit, Remi Nout, Tjalling Bosse. Histopathology 2020
40
33

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Stefania Bellone, Eliana Bignotti, Silvia Lonardi, Francesca Ferrari, Floriana Centritto, Alice Masserdotti, Francesca Pettinella, Jonathan Black, Gulden Menderes, Gary Altwerger,[...]. Gynecol Oncol 2017
33
33

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Aline Talhouk, Melissa K McConechy, Samuel Leung, Winnie Yang, Amy Lum, Janine Senz, Niki Boyd, Judith Pike, Michael Anglesio, Janice S Kwon,[...]. Cancer 2017
237
33

Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
Casper Reijnen, Heidi V N Küsters-Vandevelde, Clemens F Prinsen, Leon F A G Massuger, Marc P M L Snijders, Stefan Kommoss, Sara Y Brucker, Janice S Kwon, Jessica N McAlpine, Johanna M A Pijnenborg. Gynecol Oncol 2019
30
33

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes,[...]. Lancet Oncol 2015
382
33

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Hyun Cheol Chung, Willeke Ros, Jean-Pierre Delord, Ruth Perets, Antoine Italiano, Ronnie Shapira-Frommer, Lyudmila Manzuk, Sarina A Piha-Paul, Lei Xu, Susan Zeigenfuss,[...]. J Clin Oncol 2019
273
33

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
913
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.